Skip to main content
Premium Trial:

Request an Annual Quote

New Products: CTGT's Connective Tissue Disorder Tests


Connective Tissue Gene Tests, or CTGT, this week announced the availability of 33 new tests using its next-generation sequencing and microarray technologies.

Twenty of the new panels can be run on its High-Density Targeted Array platform, an Agilent Technologies-manufactured chip for copy number variation detection.

These include tests for genes associated with different types of spondylocostal dysotosis, Norrie disease, pseudoxanthoma elasticum, serpentine fibula-polycystic kidney syndrome, Alagille syndrome, arterial calcification, cleidocranial dysplasia, Ehlers-Danlos syndrome, exudative vitreoretinopathy, Hajdu-Cheney syndrome, hereditary hemorrhagic telangiectasia, and metaphyseal dysplasia.

The Allentown, Pa.-based company charges $1,190 per first gene tested with the array and $590 per additional genes tested.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.